title: Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence.
abstract: Vasopressin and CRH have complementary roles in the secretion of ACTH following different stress modalities. The concomitant use of V1b and CRF1 receptor antagonists completely inhibits ACTH secretion in response to different stress modalities. The combination of the CRF1 antagonist SSR125543 with the V1b antagonist SSR149415 effectively suppressed plasma ACTH 1.30 h after injection in rats stressed by ether vapor inhalation for 1 min, restraint stress for 1 h or forced swimming for 5 min. The duration of the effect was also studied. The CRF1 antagonist effectively suppressed ACTH secretion in restraint stress, while the V1b antagonist was effective against ether inhalation. Both antagonists were necessary to block the forced swimming stress response. SSR125543 induced a prolonged effect and can be used in a model of prolonged HPA axis blockade.
authors.affiliation: Department of Psychobiology, Universidade Federal de Sx00E3;o Paulo (UNIFESP), Sx00E3;o Paulo, Brazil.
authors.forename: Adriana T
authors.initials: AT
authors.lastname: Ramos
authors.forename: Sergio
authors.initials: S
authors.lastname: Tufik
authors.forename: Lanfranco R P
authors.initials: LR
authors.lastname: Troncone
mesh_terms: D000280:Administration, Inhalation; D000324:Adrenocorticotropic Hormone / Q000187:drug effects* / Q000378:metabolism; D018685:Anesthetics, Inhalation / Q000494:pharmacology; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists / Q000494:pharmacology*; D003346:Corticotropin-Releasing Hormone / Q000187:drug effects* / Q000378:metabolism; D004986:Ether / Q000494:pharmacology; D006846:Hydrocarbons, Halogenated / Q000494:pharmacology*; D007030:Hypothalamo-Hypophyseal System; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D023421:Models, Animal; D010913:Pituitary-Adrenal System; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000378:metabolism; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000378:metabolism*; D013550:Swimming; D013843:Thiazines / Q000494:pharmacology*; D014667:Vasopressins / Q000187:drug effects* / Q000378:metabolism; D000099052:CRF Receptor, Type 1
chemical_list: C456029:1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide; D018685:Anesthetics, Inhalation; D065092:Antidiuretic Hormone Receptor Antagonists; D006846:Hydrocarbons, Halogenated; D007211:Indoles; D011759:Pyrrolidines; D018019:Receptors, Corticotropin-Releasing Hormone; D017483:Receptors, Vasopressin; C502407:SSR125543; D013843:Thiazines; D004986:Ether; D014667:Vasopressins; D000099052:CRF Receptor, Type 1; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone